Insights about U.S. Stocks from mix sectors that landed in the Green-Zone in the course of Tuesday’s trade, are depicted underneath:

Intrexon Corp (NYSE:XON)’s shares picked up 19.72%, and closed at $48.15, hitting new 52-week high of $49.15, during the last trading session.

Intrexon Corporation, a leader in synthetic biology, declared its fourth quarter and full year results for 2014.

Fourth Quarter 2014 Financial Results Contrast to Preceding Year Period:

Total proceeds were $31.1 million for the quarter ended December 31, 2014 contrast to $7.1 million for the quarter ended December 31, 2013, an raise of $24.0 million, or 335%. Partnershipproceeds raised $6.0 million due to (i) the recognition of deferred proceed for upfront payments related to collaborations or expansions thereof signed by us in 2014, (ii) the recognition of research and development services performed by us following these new collaborations, and (iii) raised research and development services performed by us for collaborations in effect preceding to 2014 as a result of the progression of current programs and initiation of new programs with the collaborations. Product proceed comprises $6.5 million from the sale of pregnant cows, live calves and the sale of livestock used in production by Trans Ova. Service proceed totaling $8.6 million relates to the provision of in vitro fertilization and embryo transfer services by Trans Ova.

Total operating expenses were $50.1 million for the quarter ended December 31, 2014 contrast to $24.9 million for the quarter ended December 31, 2013, an raise of $25.2 million, or 101%. Total operating expenses for 2014 comprise $12.5 million of products and services costs which primarily comprise of employee compensation costs, livestock, feed, drug supplies and facility charges related to the production of such products and services. Research and development expenses were $17.6 million for the quarter ended December 31, 2014 contrast to $12.6 million for the quarter ended December 31, 2013, an raise of $5.0 million, or 40%. Salaries, benefits and other personnel costs raised $2.8 million due to (i) raises in research and development headcount to support new collaborations and (ii) stock-based compensation expenses for stock options granted to research and development employees in March 2014. Lab supplies and consultants raised $1.4 million as a result of the raised level of research and development services offered to our collaborators. Selling, general and administrative expenses were $19.8 million for the quarter ended December 31, 2014 contrast to $12.3 million for the quarter ended December 31, 2013, an raise of $7.5 million, or 61%. Salaries, benefits and other personnel costs raised $6.5 million due to (i) our hiring of additional employees needed to operate as a public corporation, (ii) the inclusion of Trans Ova employees in 2014, and (iii) stock-based compensation expenses for stock options granted to general and administrative employees in March 2014.

Intrexon Corporation, is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the Corporation’s proprietary UltraVector® platform and integrated technology suite, Intrexon provides its partners with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.

KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), raised 19.45%, and closed at $0.700. The stock its volatility for the week is 21.70%, while for the month it is 12.62 %. The company has the market capitalization of $19.33M. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).

KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California. KaloBios Pharmaceuticals, Inc. a biopharmaceutical corporation, primarily develops monoclonal antibody therapeutics for the treatment of respiratory diseases and cancer in the United States. Its product candidates comprise KB001-A, which is in a Phase II clinical trial for the prevention and treatment of pseudomonas aeruginosa infection in mechanically ventilated and cystic fibrosis patients; KB003 that is in a Phase II clinical trial for the treatment of inflammatory diseases; and KB004, which is in a Phase I clinical trial for the treatment of hematologic malignancies and solid tumors. The corporation has a partnership contract with Sanofi Pasteur S.A. for the development of KB001-A.

NutriSystem Inc (NASDAQ:NTRI), enhanced 12.77%, and closed at $19.34, hitting new 52-week high of $20.26.

Nutrisystem, Inc. a leading provider of weight administration products and services, stated that the Corporation achieved its formerly offered proceed, adjusted EBITDA and earnings per share guidance for the fourth quarter and 2014 fiscal year and offered an outlook for 2015.

Full Year 2014:

• Proceed raised 13% to $403.1 million, contrast to $358.1 million in 2013.
• Adjusted EBITDA grew 35% to $42.7 million, contrast to $31.6 million in 2013.
• Net revenue raised 66% to $19.3 million, contrast to adjusted net revenue of $11.6 million in 2013.
• GAAP diluted earnings per share raised 65% to $0.66 per share from adjusted earnings of $0.40 per share in 2013.
• Cash, cash equivalents, and short term investments raised $2.9 million to $29.2 million at December 31, 2014 from $26.3 million at December 31, 2013. The Corporation had no borrowings outstanding under its bank facility.
• In 2014, the Corporation returned $20.4 million in cash to stockholders via dividends. The Board of Directors has declared a quarterly dividend of $0.175 per share, payable March 23, 2015 to stockholders of record as of March 12, 2015.

Nutrisystem, Inc. is a leader in the weight loss industry, having assisted millions of people lose weight over the course of more than 40 years. The Corporation’s weight loss solutions comprise Nutrisystem® My Way®, a 28-day structured food delivery program, multi-day kits accessible at select retail outlets and a new free app and digital platform NuMi® by Nutrisystem. Nutrisystem meal plans feature a wide variety of choices, counting more than 100 foods containing no artificial preservatives or artificial flavors, together with comprehensive counseling options from trained weight-loss coaches, registered dietitians and certified diabetes educators.

iPass Inc.(NASDAQ:IPAS), rose 12.77%, and closed at $1.06.

iPass Inc. providing cost-effective Wi-Fi access around the world for enterprises and other planned partners, has formerly on February 19, declared a deal with global workplace provider, Regus plc, to allow the corporation to offer its customers packages that come with bundled global Wi-Fi access. Regus operates more than 2,000 business centers in 104 countries and its on-site Wi-Fi is a key service for many of its customers. Through partnering with iPass, Regus will be able to provide their high value customers with bundled access to 18 million Wi-Fi hotspots worldwide, counting airports, hotels, restaurants and other public areas.

“We are always looking at ways to offer greater value to our customers and we see global Wi-Fi as a great differentiator,” said Andre Sharpe, Global Product and Business Development Director at Regus. “For many of our customers, their work extends beyond the boundaries of the office, so being able to stay connected is vital. Our partnership with iPass means that we can offer an improved service to our customers by giving them access to Wi-Fi all over the world, wherever they travel or chose to work.”

iPass enables business travelers to stay connected by providing them with cost-effective and convenient global Wi-Fi access across smartphones, tablets and laptops. Founded in 1996, iPass (NASDAQ: IPAS) is the world’s largest commercial Wi-Fi network, covering over 120 countries and territories and selling to over 700 large corporations, telecom service providers and other planned partners around the world.